Phase II Avastin Trial for Stage IIIB/IV NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00766246
Recruitment Status : Terminated (Withdrawal of funding support)
First Posted : October 3, 2008
Last Update Posted : April 19, 2016
Genentech, Inc.
Information provided by (Responsible Party):

October 1, 2008
October 3, 2008
April 19, 2016
October 2008
April 2012   (Final data collection date for primary outcome measure)
Progression-free survival (PFS) of bevacizumab and pemetrexed compared to pemetrexed monotherapy during second-line treatment of Stage IIIB or IV NSCLC [ Time Frame: Duration of study ]
Same as current
Complete list of historical versions of study NCT00766246 on Archive Site
  • Overall Survival (OS) [ Time Frame: Duration of the study ]
  • Objective tumor response (objective response rate [ORR]) in second-line treatment [ Time Frame: Duration of the study ]
  • Progression-free survival (PFS) in first-line and maintenance treatment [ Time Frame: Duration of the study ]
  • Objective tumor response (objective response rate [ORR]) in first-line and maintenance treatment [ Time Frame: Duration of the study ]
  • Treatment safety in first-line, maintenance and second-line treatment [ Time Frame: Duration of the study ]
Same as current
Not Provided
Not Provided
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).
This phase II clinical trial will address the issues of bevacizumab treatment duration and treatment safety as first-line therapy for patients with non-squamous NSCLC. Following disease progression or treatment failure, the potential benefit of continued bevacizumab therapy will be tested by randomizing patients to two treatment arms, including second-line chemotherapy with or without further bevacizumab. It is hypothesized that continuation of bevacizumab with pemetrexed as second-line treatment following progression will result in improved clinical outcomes for patients with NSCLC.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Non-small Cell Lung Cancer Stage IIIB
  • Non-small Cell Lung Cancer Stage IV
  • Drug: bevacizumab
    15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
    Other Name: Avastin
  • Drug: docetaxel
    75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
    Other Name: Taxotere
  • Drug: carboplatin
    AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
    Other Name: Paraplatin
  • Experimental: First-line
    Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
    • Drug: bevacizumab
    • Drug: docetaxel
    • Drug: carboplatin
  • Experimental: Maintenance
    Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
    Intervention: Drug: bevacizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥ 18 years
  • Histologically or cytologically confirmed stage IIIB with malignant pleural effusion or stage IV NSCLC except squamous-cell carcinoma
  • Measurable disease defined by RECIST
  • Adequate organ function:

    1. Absolute neutrophil count ≥ 1.5 x 10(9)/L
    2. Hemoglobin ≥ 9.0 g/dL
    3. Platelets ≥ 100 x 10(9)/L
    4. Hepatic enzyme levels: AST and ALT and Alkaline Phosphatase must be within range allowing for eligibility. In determining eligibility, the more abnormal of the two values (AST or ALT) should be used according to table listed in the protocol
    5. Bilirubin ≤ ULN
    6. Serum Creatinine ≤ 1.5 mg/dL (or creatinine clearance ≥ 60mL/min)
    7. Urine protein/creatinine ratio < 1.0 OR urine dipstick for proteinuria < 2 + (patients discovered to have ≥ 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤1g of protein in 24 hours to be eligible)
    8. INR ≤ 1.5
    9. PTT ≤ ULN
  • ECOG Performance Status 0-1
  • Estimated survival of ≥ 12 weeks
  • Provide written informed consent

Exclusion Criteria:

  • Prior chemotherapy for advanced NSCLC
  • Neoadjuvant or adjuvant treatment within six (6) months of registration
  • Prior radiation therapy within three (3) weeks of registration; all side effects must have resolved by registration
  • Prior treatment with an investigational or marketed agent that acts by antiangiogenesis mechanisms
  • Large ( > 4 cm) centrally located lesions or large lesions in close proximity to major blood vessels unless treated with palliative radiation
  • Brain metastases or leptomeningeal disease, except for patients who have had a resection and/or completed a course of cranial irradiation, have no worsening CNS symptoms, and have discontinued all corticosteroids for that indication for at least one (1) month prior to registration
  • History of gross hemoptysis (defined as bright red blood of at least ½ teaspoon or 2.5 mL per episode) within three (3) months of registration unless definitively treated with surgery, radiation, arteriographic embolization, or endobronchial interventions at least four (4) weeks prior to registration
  • Presence of cavitory lesion
  • Presence of squamous histology (mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is not acceptable)
  • Peripheral neuropathy > grade 1
  • Major surgery, open biopsy or significant traumatic injury within four (4) weeks of registration or anticipation of need for major surgical procedure during the course of the study
  • Minor surgical procedures, fine needle aspirations or core biopsies within one (1) week prior to registration
  • Current, ongoing therapeutic anticoagulation with full-dose warfarin or its equivalent
  • Current or recent (within ten [10] days of the first dose of study treatment) use of aspirin (at least 325 mg/day) or other NSAIDs with anti-platelet activity or treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), or cilostazol (Pletal)
  • History of prior malignancy within the past three (3) years except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or treated localized prostate cancer with a current PSA of < 1.0 mg/dL on two successive evaluations, at least three (3) months apart, with the most recent evaluation no more than four (4) weeks prior to registration
  • History of serious systemic disease including:

    1. Unstable angina, New York Heart Association (NYHA) ≥ Grade II or congestive heart failure
    2. Inadequately controlled hypertension (blood pressure >150/100 mmHg while taking antihypertensive medications)
    3. Unstable symptomatic arrhythmia requiring medication
    4. Myocardial infarction within six (6) months prior to registration
    5. Stroke within six (6) months prior to registration
    6. Transient ischemic attack within six (6) months prior to registration
    7. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within six (6) months prior to registration
    8. Clinically significant peripheral vascular disease or evidence of bleeding, diathesis (prone to bleeding) or coagulopathy
    9. Active systemic bacterial, fungal or viral infection, including known HCV and HIV
  • Pregnancy or women who are breast-feeding; women of child-bearing potential and non-vasectomized men must agree to use effective methods of birth control during and three (3) months following treatment period and women of child-bearing potential must have a negative pregnancy test
  • History of severe hypersensitivity reaction to docetaxel or any other drugs formulated with polysorbate 80
  • Any other medical condition, including mental illness or substance abuse, which in the judgment of the investigator, is likely to interfere with a patient's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results
  • Use of any investigational agent within four (4) weeks prior to registration
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
PSHCI 08-009
Not Provided
Plan to Share IPD: Yes
  • Genentech, Inc.
  • Sanofi
Principal Investigator: Chandra P Belani, MD Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Cancer Institute
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP